Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Study Assessing Effectiveness, Safety and Compliance With Fexinidazole in Patients With Human African Trypanosomiasis Due to T.b. Gambiense at Any Stage

NCT03025789 is registered in ClinicalTrials.gov with Drugs for Neglected Diseases as lead sponsor.

NCT NCT03025789
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03025789 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Study Assessing Effectiveness, Safety and Compliance With Fexinidazole in Patients With Human African Trypanosomiasis Due to T.b. Gambiense at Any Stage
Lead sponsor
Drugs for Neglected Diseases
Phase
Phase 3
Overall status
Completed
Start date
November 10, 2016
Completion date
February 1, 2021
Enrollment
174 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

sleeping sickness, trypanosomiasis, african, trypanosomiasis; gambian